Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMJWD62)

Drug Name
phorbol 12-myristate 13-acetate Drug Info
Synonyms TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate
Cross-matching ID
PubChem CID
27924
ChEBI ID
CHEMBL279115
CAS Number
CAS 16561-29-8
TTD Drug ID
D09DHT

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
TNF signaling pathway 2.65 0.00e+0 103/112 (91.96%) CXCL1;CCL20;PTGS2;...
IL-17 signaling pathway 2.64 0.00e+0 84/94 (89.36%) MMP1;CXCL8;CXCL1;...
Rheumatoid arthritis 2.53 0.00e+0 78/93 (83.87%) MMP1;CXCL8;CXCL1;...
NF-kappa B signaling pathway 2.36 0.00e+0 90/104 (86.54%) CXCL8;CXCL1;PTGS2;...
Cytokine-cytokine receptor interaction 2.34 0.00e+0 246/295 (83.39%) CXCL8;CXCL1;INHBA;...
Kaposi sarcoma-associated herpesvirus infection 2.33 0.00e+0 172/193 (89.12%) CXCL8;CXCL1;PTGS2;...
NOD-like receptor signaling pathway 2.32 0.00e+0 145/181 (80.11%) CXCL8;CXCL1;TNFAIP3;...
Malaria 2.31 0.00e+0 44/50 (88%) CXCL8;ICAM1;CCL2;...
ECM-receptor interaction 2.27 0.00e+0 80/88 (90.91%) LAMC2;LAMB3;SDC4;...
C-type lectin receptor signaling pathway 2.23 0.00e+0 93/104 (89.42%) PTGS2;RELB;EGR3;...
Epithelial cell signaling in Helicobacter pylori infect... 2.22 0.00e+0 62/70 (88.57%) CXCL8;CXCL1;CXCL3;...
Focal adhesion 2.21 0.00e+0 180/201 (89.55%) LAMC2;LAMB3;BIRC3;...
Viral protein interaction with cytokine and cytokine re... 2.18 0.00e+0 84/100 (84%) CXCL8;CXCL1;CCL20;...
AGE-RAGE signaling pathway in diabetic complications 2.15 0.00e+0 97/100 (97%) CXCL8;ICAM1;CCL2;...
Amoebiasis 2.13 0.00e+0 99/102 (97.06%) CXCL8;CXCL1;LAMC2;...
Hematopoietic cell lineage 2.13 0.00e+0 90/99 (90.91%) CD9;CD55;IL6;...
Chemokine signaling pathway 2.12 0.00e+0 163/192 (84.9%) CXCL8;CXCL1;CCL20;...
Yersinia infection 2.11 0.00e+0 120/137 (87.59%) CXCL8;CCL2;IL6;...
Human cytomegalovirus infection 2.10 0.00e+0 201/225 (89.33%) CXCL8;PTGS2;CCL2;...
Osteoclast differentiation 2.10 0.00e+0 117/127 (92.13%) FOSL1;RELB;NFKBIA;...
Pathogenic Escherichia coli infection 2.10 0.00e+0 152/197 (77.16%) CXCL8;IL6;NFKBIA;...
Th17 cell differentiation 2.09 0.00e+0 95/107 (88.79%) IL6;NFKBIA;SMAD3;...
Bladder cancer 2.08 0.00e+0 40/41 (97.56%) MMP1;CXCL8;MMP9;...
Shigellosis 2.07 0.00e+0 180/246 (73.17%) CXCL8;TNIP1;NFKBIA;...
PI3K-Akt signaling pathway 2.06 0.00e+0 317/354 (89.55%) AREG;LAMC2;LAMB3;...
Lipid and atherosclerosis 2.02 4.04e-4 190/215 (88.37%) MMP1;CXCL8;CXCL1;...
JAK-STAT signaling pathway 2.01 3.89e-4 146/162 (90.12%) LIF;IL6;IL13RA2;...
Prostate cancer 2.01 3.75e-4 93/97 (95.88%) PLAT;MMP9;PLAU;...
Small cell lung cancer 2.00 3.62e-4 90/92 (97.83%) LAMC2;PTGS2;LAMB3;...
Fluid shear stress and atherosclerosis 1.98 6.56e-4 123/139 (88.49%) PLAT;ICAM1;MMP9;...
Propanoate metabolism -1.68 1.26e-2 30/34 (88.24%) ACACA;ACAT2;DBT;...
Histidine metabolism -1.69 1.08e-2 16/22 (72.73%) ALDH3B1;MAOA;ALDH9A1;...
Nucleotide excision repair -1.69 1.12e-2 40/47 (85.11%) GTF2H3;POLE3;POLE;...
Peroxisome -1.69 1.13e-2 72/82 (87.8%) PEX1;SLC25A17;ABCD4;...
beta-Alanine metabolism -1.69 1.17e-2 25/30 (83.33%) DPYD;DPYS;AOC3;...
Steroid hormone biosynthesis -1.73 9.33e-3 43/61 (70.49%) AKR1C3;UGT2B17;AKR1C2;...
Terpenoid backbone biosynthesis -1.78 5.23e-3 18/22 (81.82%) HMGCR;DHDDS;ACAT2;...
Linoleic acid metabolism -1.78 5.07e-3 21/29 (72.41%) CYP1A2;CYP2J2;PLA2G6;...
Cysteine and methionine metabolism -1.79 5.30e-3 43/50 (86%) TST;ENOPH1;BCAT2;...
Lysine degradation -1.79 5.12e-3 51/63 (80.95%) ALDH9A1;GCDH;EZH1;...
Spliceosome -1.80 4.48e-3 101/150 (67.33%) TRA2A;MAGOH;PRPF38B;...
Glyoxylate and dicarboxylate metabolism -1.82 3.30e-3 23/30 (76.67%) PCCB;SHMT2;HAO1;...
Homologous recombination -1.83 3.49e-3 35/41 (85.37%) BABAM2;PALB2;RAD52;...
DNA replication -1.83 3.69e-3 34/36 (94.44%) MCM6;RFC3;POLA2;...
One carbon pool by folate -1.84 3.36e-3 15/20 (75%) SHMT2;FTCD;TYMS;...
Pentose and glucuronate interconversions -1.87 2.99e-3 17/34 (50%) CRYL1;UGT2B17;UGT2A3;...
RNA transport -1.88 3.20e-3 128/186 (68.82%) GEMIN6;EEF1A2;SUMO3;...
Metabolism of xenobiotics by cytochrome P450 -1.90 2.07e-3 49/77 (63.64%) GSTA3;CYP1A1;CBR1;...
Tryptophan metabolism -1.93 2.24e-3 35/42 (83.33%) CYP1A2;MAOA;CYP1B1;...
Fanconi anemia pathway -1.94 2.45e-3 36/54 (66.67%) PALB2;FANCL;RAD51;...
Butanoate metabolism -1.94 1.79e-3 23/28 (82.14%) ACAT2;HMGCS2;ACSM5;...
Ribosome -2.00 9.96e-4 113/158 (71.52%) MRPS16;RPS27A;RPS3A;...
Drug metabolism -2.02 1.12e-3 78/151 (51.66%) GSTK1;UMPS;UGT2B17;...
Mismatch repair -2.02 1.28e-3 22/23 (95.65%) RFC1;EXO1;RPA3;...
Porphyrin and chlorophyll metabolism -2.04 1.49e-3 23/43 (53.49%) PPOX;UGT2B17;UGT2A3;...
Retinol metabolism -2.04 1.79e-3 41/68 (60.29%) UGT2B17;CYP2C18;DGAT1;...
Valine, leucine and isoleucine degradation -2.07 0.00e+0 42/48 (87.5%) MCCC2;ACAT2;DBT;...
Phenylalanine metabolism -2.08 0.00e+0 14/17 (82.35%) GOT1;AOC3;ALDH3B1;...
Glycine, serine and threonine metabolism -2.38 0.00e+0 31/40 (77.5%) AOC3;SHMT2;MAOA;...
Tyrosine metabolism -2.44 0.00e+0 30/36 (83.33%) ADH5;COMT;GOT1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 10uM 6H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 8uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.002uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.006uM - 8uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.006uM - 8uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.006uM - 8uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 10uM 6H
HT-29 CVCL_0320 Homo sapiens 0.006uM - 10uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 10uM 6H
MDST8 CVCL_1400 Homo sapiens 10uM 6H
NCI-H508 CVCL_1561 Homo sapiens 10uM 6H
SNU-1040 CVCL_5001 Homo sapiens 10uM 6H
SNU-C4 CVCL_5008 Homo sapiens 10uM 6H
SNU-C5 CVCL_5009 Homo sapiens 10uM 6H
SW480 CVCL_0546 Homo sapiens 10uM 6H
SW620 CVCL_0547 Homo sapiens 10uM 6H
SW948 CVCL_0550 Homo sapiens 10uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 10uM 6H
HT115 CVCL_1294 Homo sapiens 10uM 6H
RKO CVCL_0504 Homo sapiens 10uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 10uM 6H
SNG-M CVCL_1707 Homo sapiens 10uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 10uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.006uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.006uM - 8uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 2.5uM - 10uM 6H, 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 2.5uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.002uM - 10uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 10uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 10uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 10uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 10uM 6H
T3M-10 CVCL_1729 Homo sapiens 10uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 10uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 10uM 6H
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 10uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 10uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 10uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 10uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 10uM 6H
OV7 CVCL_1623 Homo sapiens 10uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 10uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 10uM 6H
RMUG-S CVCL_1666 Homo sapiens 10uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.006uM - 8uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.006uM - 10uM 6H, 24H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HL-60 CVCL_0002 Homo sapiens 0.37uM - 10uM 6H, 24H
NOMO-1 CVCL_1609 Homo sapiens 10uM 6H
PL-21 CVCL_2161 Homo sapiens 10uM 6H
SKM-1 CVCL_0010 Homo sapiens 10uM 6H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.03uM - 8uM 24H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 0.37uM - 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.006uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.006uM - 10uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 10uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 10uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 10uM 6H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.006uM - 8uM 24H